Commenting on his departure, Dr Tillett said: “I am very proud of the team at Race for their outstanding work in advancing Zantrene back to clinic. My confidence that Zantrene will prove to be both a commercial and medical success has continued to grow in recent months, and I believe Zantrene has the potential to improve the lives of millions of cancer patients. I have full faith that our CEO Damian and the Race clinical and preclinical teams have the capability, skill, and drive to ensure Race’s success.”
I guess many shareholders were surprised and saddened at your decision to depart RAC management.
The share price perhaps , at this time , reflects that .
I would assume that your above departing statement still holds in all aspects ?
General Comments / Chat, page-8138
-
- There are more pages in this discussion • 2,988 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |